viewRedx Pharma PLC

Redx Pharma plc - Redx ROCK2 inhibitors poster to be presented

RNS Number : 6870E
Redx Pharma plc
22 October 2018


("Redx" or "the Company")


Redx ROCK2 inhibitors poster to be presented at the ASN Kidney Week 2018 in San Diego


Alderley Park, 22 October 2018 Redx (AIM: REDX), the drug development company focused on cancer and fibrosis, is pleased to announce that the Company's poster, entitled 'ROCK2 inhibitors for the treatment of chronic kidney disease' will be presented at the American Society of Nephrology (ASN) Kidney Week 2018 in San Diego, CA, on 25 October 2018 from 10:00am to 12:00pm.


The title, timing and location of the poster presentation is as follows:


Abstract Number:



ROCK2 inhibitors for the treatment of chronic kidney disease


Thursday, 25 October 2018


Poster Board #: TH-PO877


10:00 AM to 12:00 PM PDT


Diabetic Kidney Disease: Basic - I [PO0601-1]

Session Type:

Poster Presentation


The full abstract of the presentation can be found below and here: https://www.asn-online.org/education/kidneyweek/2018/program-abstract.aspx?controlId=3014989




The Rho Associated Coiled-Coil Containing Protein Kinase (ROCK) serine/threonine kinases, ROCK1 and ROCK2, are central signalling proteins that regulate a range of cellular responses such as cell migration, contraction, proliferation, cytokine and growth factor expression, and integrin-mediated cell-to-cell adhesions. These processes are central to the aberrant wound healing response that can progress to chronic injury and organ fibrosis. Small molecule pan-ROCK inhibitors have been shown to be anti-fibrotic in a range of animal models including: bleomycin induced lung fibrosis, high fat diet induced liver fibrosis and models of kidney fibrosis. However, ROCK signalling is also involved in regulating vascular tone and pan-ROCK inhibitors have been shown to cause hyperaemia and hypotension, limiting their use in patients. There is significant homology between the ROCK1 and ROCK2 isoforms however there is evidence that ROCK2 has additional roles distinct from ROCK1 in both inflammation and wound healing. For example, ROCK2 is upregulated in diabetic kidney disease and in the diseased vascular network of patients at risk of chronic kidney disease (CKD).



Redx have developed a series of potent ROCK2 inhibitors, that are highly selective against ROCK1 and a panel of 468 kinases.



Redx ROCK2 selective compounds potently suppress the release of pro-fibrotic factors from kidney mesangial cells, cultured in high glucose. In a model of acute kidney injury, our selective ROCK2 tool compound reduced podocyte damage, and the expression of inflammatory and profibrotic genes in the kidney.


In addition, in a telemetered rat study, no significant reduction in blood pressure or increase in heart rate was recorded, indicating that a selective ROCK2 inhibitor could avoid these side-effects typically observed with pan-ROCK inhibitors and increase the safety window at efficacious doses.




Highly selective ROCK2 inhibitors, therefore, could provide a novel and effective therapy for patients with progressive kidney fibrosis who currently have few and largely ineffective therapy options.


For further information, please contact:


Redx Pharma Plc

T: +44 1625 469 920

Lisa Anson, Chief Executive Officer

Andrew Saunders, Chief Medical Officer




Cantor Fitzgerald Europe (Nominated Advisor & Broker)

 T: +44 20 7894 7000

Phil Davies




WG Partners LLP (Joint Broker)

T: +44 20 3705 9330

Claes Spång/ Chris Lee/ David Wilson





FTI Consulting

T: +44 20 3727 1000

Simon Conway/Stephanie Cuthbert



About Redx Pharma Plc 


Redx is a UK biotechnology company whose shares are traded on AIM (AIM:REDX). Redx's vision is to become a leading biotech focused on the development of novel precision medicines that have the potential to transform treatment in oncology and fibrotic diseases.


If you would like to sign up to regular alerts from Redx Pharma, please follow this link https://www.redxpharma.com/investors/email-alerts/.



This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

Quick facts: Redx Pharma PLC

Price: 12.55

Market: AIM
Market Cap: £23.85 m

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Redx Pharma PLC's Lisa Anson updates on lead asset RXC004 and increased...

Redx Pharma PLC's (LON:REDX) Lisa Anson recaps on its lead product RXC004 which is in a Phase I clinical trial and is part of a potentially breakthrough group of cancer drugs called Porcupine inhibitors. Anson also details the recent investment by its majority shareholder Redmile which has...

1 hour, 39 minutes ago